First-To-Market Calliditas Picking Up Speed In IgA Nephropathy
A few hiccups aside, Tarpeyo is on track in the US, but major competition from Novartis is just round the corner.
A few hiccups aside, Tarpeyo is on track in the US, but major competition from Novartis is just round the corner.